• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, Nov. 29 Indian pharma companies should actively explore acquisition and joint venture feasibilities in Europe, according to Mr K.V. Raghavan, Chairman of Recruitment and Assessment Centre (RAC), Defence Research and Development Organisation (DRDO).

Speaking at a European Union – India roundtable on pharma sector here on Thursday, Mr Raghavan said manpower, regulatory frameworks, growing biotech capabilities and a forward looking corporate structure were the advantages for Indian pharma industry.

“These strengths should be leveraged to form joint ventures with pharma companies in Europe and acquisitions,” he said. The growth in the EU generics market in Germany, France and the UK and wider product availability would particularly favour joint ventures between India and European Union, he added.

The programme was organised by European Union India Investment Facilitation Desk.

More Stories on : Pharmaceuticals | Andhra Pradesh

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Fuel efficiency grades for automobiles on the anvil

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line